一项新的研究发现,先进的肾癌患者在免疫后接受治疗后,药物组合延长寿命,但会产生更多副作用。 A new study found a drug combo extends life for advanced kidney cancer patients post-immunotherapy, though with more side effects.

在2025年ESMO大会(LenCabo案审判)上提出的第二阶段试验,即LenCabo案的试验发现,将伦瓦蒂尼布和埃沃利穆斯结合在一起,使在免疫治疗后取得进步的高级肾癌患者的无进展存活率提高到15.7个月,而Cabozantinib为10.2个月。 A Phase II trial presented at the 2025 ESMO Congress, the LenCabo trial, found that combining lenvatinib and everolimus improved progression-free survival to 15.7 months in advanced kidney cancer patients who had progressed after immunotherapy, compared to 10.2 months with cabozantinib. 该研究涉及86至90名患有经转移的明显细胞肾脏癌的病人。 研究表明,综合治疗在统计学上大有裨益,尽管严重副作用和停止治疗的比率较高。 The study, involving 86 to 90 patients with metastatic clear cell renal cell carcinoma, showed a statistically significant benefit with the combination, though it had higher rates of severe side effects and treatment discontinuation. 这是对这些二线治疗方法的第一次直接比较,表明在免疫治疗失败后,这种结合可能是更有效的选择,尽管毒性仍然是一个令人关切的问题。 This was the first direct comparison of these second-line treatments, suggesting the combination may be a more effective option after immunotherapy failure, though toxicity remains a concern.